# A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma

> **NCT05324501** · PHASE1 · TERMINATED · sponsor: **Biodexa Pharmaceuticals** · enrollment: 4 (actual)

## Conditions studied

- Recurrent Glioblastoma

## Interventions

- **DRUG:** MTX110
- **DEVICE:** Programmable pump and catheter system

## Key facts

- **NCT ID:** NCT05324501
- **Lead sponsor:** Biodexa Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-10-19
- **Primary completion:** 2024-09-10
- **Final completion:** 2024-09-10
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Strategic decision
- **Last updated:** 2025-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05324501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05324501, "A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05324501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*